Korean J Gastroenterol.  2013 Oct;62(4):189-190. 10.4166/kjg.2013.62.4.189.

The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Indicator for Bile Duct and Gallbladder Cancer: Need for a Prospective Study Using Various Quantitative Parameters

• Eo JS
• Choe JG

• KMID: 1792736
• DOI: http://doi.org/10.4166/kjg.2013.62.4.189

Abstract

No abstract available.

Reference

References

1. Kim JY, Kim MH, Lee TY, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008; 103:1145–1151.

2. Lee SW, Kim HJ, Park JH, et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol. 2010; 45:560–566.

3. Petrowsky H, Wildbrett P, Husarik DB, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 2006; 45:43–50.

4. Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001; 33:1029–1035.

5. Corvera CU, Blumgart LH, Akhurst T, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008; 206:57–65.

6. Kitamura K, Hatano E, Higashi T, et al. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. J Hepatobiliary Pancreat Sci. 2011; 18:39–46.

7. Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008; 143:769–777.

8. Lee JY, Kim HJ, Yim SH, et al. Primary tumor maximum standardized uptake value measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer. Korean J Gastroenterol. 2013; 62:227–233.

9. Furukawa H, Ikuma H, Asakura K, Uesaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009; 100:494–499.

10. Chung HH, Kim JW, Han KH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011; 120:270–274.

11. Hyun SH, Choi JY, Shim YM, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010; 17:115–122.

12. Choi KH, Yoo IR, Han EJ, et al. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinomas treated by surgery. Nucl Med Mol Imaging. 2011; 45:43–51.

13. Yoo J, Choi JY, Lee KT, et al. Prognostic significance of vol-ume-based metabolic parameters by 18F-FDG PET/CT in gallbladder carcinoma. Nucl Med Mol Imaging. 2012; 46:201–206.